Search results for PX-TA1407

Satralizumab Biosimilar – Anti-IL6R mAb – Research Grade, ProteoGenix, PX-TA1407

Description of Satralizumab Biosimilar - Anti-IL6R mAb - Research Grade General information on Anti-IL6R[Homo sapiens] (Satralizumab) Monoclonal Antibody Satralizumab is a humanized monoclonal antibody that targets human interleukin-6 (IL-6) receptors, similar to tocilizumab. Satralizumab is used to treat neuromyelitis optica spectrum disorder (NMOSD). Increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased permeability of the blood-brain barrier are thought to be mediated by IL-6. Satralizumab is thought to block IL-6 receptors and, thereby, these inflammatory responses.